162 related articles for article (PubMed ID: 30398433)
1. Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study.
Kuhl CK; Alparslan Y; Schmoee J; Sequeira B; Keulers A; Brümmendorf TH; Keil S
Radiology; 2019 Feb; 290(2):349-356. PubMed ID: 30398433
[TBL] [Abstract][Full Text] [Related]
2. Target lesion selection: an important factor causing variability of response classification in the Response Evaluation Criteria for Solid Tumors 1.1.
Keil S; Barabasch A; Dirrichs T; Bruners P; Hansen NL; Bieling HB; Brümmendorf TH; Kuhl CK
Invest Radiol; 2014 Aug; 49(8):509-17. PubMed ID: 24651664
[TBL] [Abstract][Full Text] [Related]
3. CT-based whole-body tumor volumetry versus RECIST 1.1: Feasibility and implications for inter-reader variability.
Zimmermann M; Kuhl CK; Engelke H; Bettermann G; Keil S
Eur J Radiol; 2021 Feb; 135():109514. PubMed ID: 33401109
[TBL] [Abstract][Full Text] [Related]
4. Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1.
Oubel E; Bonnard E; Sueoka-Aragane N; Kobayashi N; Charbonnier C; Yamamichi J; Mizobe H; Kimura S
Acad Radiol; 2015 Feb; 22(2):217-25. PubMed ID: 25488429
[TBL] [Abstract][Full Text] [Related]
5. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.
Zacharia TT; Saini S; Halpern EF; Sumner JE
AJR Am J Roentgenol; 2006 Apr; 186(4):1067-70. PubMed ID: 16554580
[TBL] [Abstract][Full Text] [Related]
6. Components of Radiologic Progressive Disease Defined by RECIST 1.1 in Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Coy HJ; Douek ML; Ruchalski K; Kim HJ; Gutierrez A; Patel M; Sai V; Margolis DJA; Kaplan A; Brown M; Goldin J; Raman SS
Radiology; 2019 Jul; 292(1):103-109. PubMed ID: 31084479
[TBL] [Abstract][Full Text] [Related]
7. Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.
Lai YC; Chang WC; Chen CB; Wang CL; Lin YF; Ho MM; Cheng CY; Huang PW; Hsu CW; Lin G
Acta Radiol; 2020 Jul; 61(7):983-991. PubMed ID: 31739675
[TBL] [Abstract][Full Text] [Related]
8. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
9. Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria.
Goebel J; Hoischen J; Gramsch C; Schemuth HP; Hoffmann AC; Umutlu L; Nassenstein K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2527-2533. PubMed ID: 28825135
[TBL] [Abstract][Full Text] [Related]
10. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
11. Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations.
Siegel MJ; Ippolito JE; Wahl RL; Siegel BA
Radiol Imaging Cancer; 2023 Sep; 5(5):e230001. PubMed ID: 37540134
[TBL] [Abstract][Full Text] [Related]
12. Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria.
Suzuki C; Torkzad MR; Jacobsson H; Aström G; Sundin A; Hatschek T; Fujii H; Blomqvist L
Acta Oncol; 2010 May; 49(4):509-14. PubMed ID: 20397778
[TBL] [Abstract][Full Text] [Related]
13. Semiquantitative visual approach to scoring lung cancer treatment response using computed tomography: a pilot study.
Gottlieb RH; Kumar P; Loud P; Klippenstein D; Raczyk C; Tan W; Lu J; Ramnath N
J Comput Assist Tomogr; 2009; 33(5):743-7. PubMed ID: 19820504
[TBL] [Abstract][Full Text] [Related]
14. RECIST 1.1 Target Lesion Categorical Response in Metastatic Renal Cell Carcinoma: A Comparison of Conventional versus Volumetric Assessment.
Gong AJ; Ruchalski K; Kim HJ; Douek M; Gutierrez A; Patel M; Sai V; Coy H; Villegas B; Raman S; Goldin J
Radiol Imaging Cancer; 2023 Sep; 5(5):e220166. PubMed ID: 37656041
[TBL] [Abstract][Full Text] [Related]
15. Observer variability in a phase II trial - assessing consistency in RECIST application.
Skougaard K; McCullagh MJ; Nielsen D; Hendel HW; Jensen BV; Johannesen HH
Acta Oncol; 2012 Jul; 51(6):774-80. PubMed ID: 22432439
[TBL] [Abstract][Full Text] [Related]
16. Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study.
Fowler KJ; Tang A; Santillan C; Bhargavan-Chatfield M; Heiken J; Jha RC; Weinreb J; Hussain H; Mitchell DG; Bashir MR; Costa EAC; Cunha GM; Coombs L; Wolfson T; Gamst AC; Brancatelli G; Yeh B; Sirlin CB
Radiology; 2018 Jan; 286(1):173-185. PubMed ID: 29091751
[TBL] [Abstract][Full Text] [Related]
17. [Follow-up CT measurement of liver malignoma according to RECIST and WHO vs. volumetry].
Heussel CP; Meier S; Wittelsberger S; Götte H; Mildenberger P; Kauczor HU
Rofo; 2007 Sep; 179(9):958-64. PubMed ID: 17594629
[TBL] [Abstract][Full Text] [Related]
18. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
19. Interobserver Variation in Response Evaluation Criteria in Solid Tumors 1.1.
Karmakar A; Kumtakar A; Sehgal H; Kumar S; Kalyanpur A
Acad Radiol; 2019 Apr; 26(4):489-501. PubMed ID: 29934024
[TBL] [Abstract][Full Text] [Related]
20. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
